Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEL116472 mechanistic study of belimumab in membranous nephropathy
2012-000385-38Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belimumab in membranous glomerulonephritis (MGN), sponsored by GSK. Primary endpoint: Change from baseline in proteinuria levels at week 28. Started Apr 2012; status: completed.
02
Drugs
belimumab
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on 2012-000385-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000385-38.